Similar articles

• [Results of treatment with sulfasalazine in the American Multicenter Study on the treatment of Crohn disease (National Cooperative Crohn's Disease Study)].

  Singleton JW. Singleton JW. Z Gastroenterol Verh. 1981 Jun;19:38-40. Z Gastroenterol Verh. 1981. PMID: 6168133 Clinical Trial. German. No abstract available.
• [Clinical effect of salazosulfapyridine (salazopyrin) in Crohn's disease. A controlled double-blind investigation].

  Anthonisen P, Bárány F, Folkenborg O, Holtz A, Jarnum S, Kristensen M, Riis P, Walan A, Worning H. Anthonisen P, et al. Ugeskr Laeger. 1974 Aug 5;136(32):1798-802. Ugeskr Laeger. 1974. PMID: 4153180 Clinical Trial. Danish. No abstract available.
• Shortcomings of the National Crohn's Disease Study: the exclusion of azathioprine without adequate trial.

  Korelitz BI, Present DH. Korelitz BI, et al. Gastroenterology. 1981 Jan;80(1):193-6. Gastroenterology. 1981. PMID: 6108892 No abstract available.
• Current treatment for prevention of relapse and recurrence in Crohn's disease.

  Prantera C, Scribano ML. Prantera C, et al. Ital J Gastroenterol Hepatol. 1999 Aug-Sep;31(6):515-8. Ital J Gastroenterol Hepatol. 1999. PMID: 10575572 Review.
• Natalizumab: a new hope for Crohn's disease?

  Napier J, Wong RK. Napier J, et al. Am J Gastroenterol. 2003 May;98(5):1197-9. doi: 10.1111/j.1572-0241.2003.07463.x. Am J Gastroenterol. 2003. PMID: 12830820 Review. No abstract available.